`
`Lucentis Prefilled Syringe
`
`Technical Review
`
`PF on behalf of the Technical Team
`February 16, 2012
`
`th NovARTIs
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`NOVITC(CH)00885630
`Novartis Exhibit 2254.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Purpose of todays Technical Review meeting
`
`
`
`" Report progress and new issues
`
`" Endorsementof team proposal regarding sterilization
`
`* Acknowledgementof current timelines
`
`« Agreement on remaining key risks (technical, regulatory)
`
`* Get buy-in and support from LFs for non standard
`timelines to submission
`
`
`
`tl, NOVARTIS
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)00885630
`
`Novartis Exhibit 2254.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`Agenda
`
`Executive summary
`
`~. Update PFS development
`
`Slide 4
`
`Slides 5 - 11
`
`Decision regarding sterilization
`
`Slide 12
`
`Next steps & milestones to submission
`
`Slides 13-16
`
`Remaining Key Risks/
`Challenges and Progress
`
`2. Back-up
`
`Slides 17 - 20
`
`Slides 22 - 39
`
`
`
`
`
`odas th, NOVARTIS
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)00885630
`
`Novartis Exhibit 2254.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`